Dan Petrylak, MD, discusses 2 case studies that focus on metastatic castration-sensitive prostate cancer, with emphasis on the use of abiraterone to treat the disease.
EP. 1: Case 1: An 80-Year-Old Man With mCSPC
Dan Petrylak, MD, presents our first case for discussion, an 80-year-old man with metastatic castration-sensitive prostate cancer (mCSPC). Front-line therapy options and monitoring for mCSPC are also mentioned.
EP. 2: mCSPC and the TITAN Study
Dr Petrylak recalls the study design and results of the TITAN study.
EP. 3: Unmet Needs and Key Takeaways When Treating mCSPC
An expert explains the unmet needs in the mCSPC landscape, as well as key takeaways if you are treating patients with this disease.
EP. 4: Case 2 Introduction: A 62-Year-Old Man With mCSPC and Front-Line Approach
Dr Petrylak presents our second case, a 62-year-old man with mCSPC.
EP. 5: Using Abiraterone as a Front-Line Therapy for mCSPC and PEACE-1 Trial Details
Dan Petrylak, MD, discusses the pros and cons of using abiraterone as a front-line therapy for mCSPC and provides details of the PEACE-1 study.
2 Clarke Drive Cranbury, NJ 08512